Results from a phase I/II trial for olutasidenib (NCT03684811) and from a phase I/II trial for enasidenib (NCT02273739) among patients with advanced or metastatic CCA and respective IDH1 or IDH2 mutations are pending. Here, IDH2 is linked to cholangiocarcinoma.